A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

NCT03922477 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
13
Enrollment
INDUSTRY
Sponsor class

Stopped The Sponsor decided to discontinue the development of atezolizumab in combination with magrolimab in the AML indication.

Conditions

Interventions

Sponsor

Hoffmann-La Roche